Abstract: Objective To study the incidence of cinepazide maleate related hematologic adverse drug reaction by monitoring software. Method The research objects were screened out by adverse drug events’ active surveillance and assessment system developed by our hospital. The collected data of the hospitalized patients in General Hospital of PLA who received cinepazide maleate between August 1, 2015 and July 31, 2016 were analyzed retrospectively. Alarm cases submitted by system were evaluated by 2 professionals. Results A total of 3 181 patients using cinepazide maleate were automatically monitored. The incidences of thrombocytopenia and leukopenia were 0.14% and 0.28%, respectively, which were consistent with the literature’s report, only 1 case without granulocytopenia in 8 cases of leukopenia. The incidence of anemia was 0.48%, it was a new ADR. The total incidence of hemocytopenia was about 0.72%, severe ADR was not observed. The average age is 69, there was no statistical difference in different age groups. Conclusion By using the automatic surveillance and assessment system, pharmacists can effectively and accurately screen the hematologic ADR induced by cinepazide. The incidence of hemocytopenia was between 0.1% and 1.0%, severe granulocytopenia was not observed. The incidence of anemia was relatively high. The ADRs caused by cinepazide can be prevented effectively and discovered as early as possible by fully understanding medication history and strengthening hemogram monitoring.

Key words: cinepazide maleate, adverse drug reaction, automatic surveillance, white brood cell decreased, blood platelet decreased, anemia